BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 30522488)

  • 1. Aldehyde dehydrogenase serves as a biomarker for worse survival profiles in ovarian cancer patients: an updated meta-analysis.
    Xia Y; Wei X; Gong H; Ni Y
    BMC Womens Health; 2018 Dec; 18(1):199. PubMed ID: 30522488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of cancer stem cell marker aldehyde dehydrogenase in ovarian cancer: a meta-analysis.
    Liu S; Liu C; Min X; Ji Y; Wang N; Liu D; Cai J; Li K
    PLoS One; 2013; 8(11):e81050. PubMed ID: 24282568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Significance of the Metabolic Marker Hexokinase-2 in Various Solid Tumors: A Meta-Analysis.
    Liu Y; Wu K; Shi L; Xiang F; Tao K; Wang G
    PLoS One; 2016; 11(11):e0166230. PubMed ID: 27824926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of pretreatment thrombocytosis with prognosis in ovarian cancer: a systematic review and meta-analysis.
    Ye Q; Cheng J; Ye M; Liu D; Zhang Y
    J Gynecol Oncol; 2019 Jan; 30(1):e5. PubMed ID: 30479089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kallikrein expression as a prognostic factor in ovarian cancer: a systematic review and meta-analysis.
    Wu Y; Lu M; Zhou Q
    J BUON; 2015; 20(3):855-61. PubMed ID: 26214640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic implication of slug in all tumour patients - a systematic meta-analysis.
    Huang C; Zhang P; Zhang D; Weng X
    Eur J Clin Invest; 2016 May; 46(5):398-407. PubMed ID: 26919035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet-lymphocyte ratio acts as an independent predictor of prognosis in patients with renal cell carcinoma.
    Wang Z; Peng S; Wang A; Xie H; Guo L; Jiang N; Niu Y
    Clin Chim Acta; 2018 May; 480():166-172. PubMed ID: 29462592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated Analysis Reveals That Long Non-Coding RNA TUBA4B Can Be Used as a Prognostic Biomarker in Various Cancers.
    Zhang T; Wu DM; Deng SH; Han R; Liu T; Li J; Xu Y
    Cell Physiol Biochem; 2018; 49(2):530-544. PubMed ID: 30157490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Ki-67 Immunohistochemical Reactivity Correlates With Poor Prognosis in Bladder Carcinoma: A Comprehensive Meta-Analysis with 13,053 Patients Involved.
    Luo Y; Zhang X; Mo M; Tan Z; Huang L; Zhou H; Wang C; Wei F; Qiu X; He R; Chen G
    Medicine (Baltimore); 2016 Apr; 95(15):e3337. PubMed ID: 27082587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-reactive protein is a predictor of prognosis in renal cell carcinoma patients receiving tyrosine kinase inhibitors: A meta-analysis.
    Wang Z; Peng S; Wang A; Xie H; Guo L; Jiang N; Niu Y
    Clin Chim Acta; 2017 Dec; 475():178-187. PubMed ID: 29080691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis.
    Wu B; Sun C; Feng F; Ge M; Xia L
    J Exp Clin Cancer Res; 2015 May; 34(1):44. PubMed ID: 25967234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Dicer as a prognostic predictor for survival in cancer patients: a systematic review with a meta-analysis.
    Shan W; Sun C; Zhou B; Guo E; Lu H; Xia M; Li K; Weng D; Lin X; Meng L; Ma D; Chen G
    Oncotarget; 2016 Nov; 7(45):72672-72684. PubMed ID: 27682871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis.
    Yuan X; Zhang J; Li D; Mao Y; Mo F; Du W; Ma X
    Gynecol Oncol; 2017 Oct; 147(1):181-187. PubMed ID: 28698008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
    Ruscito I; Cacsire Castillo-Tong D; Vergote I; Ignat I; Stanske M; Vanderstichele A; Ganapathi RN; Glajzer J; Kulbe H; Trillsch F; Mustea A; Kreuzinger C; Benedetti Panici P; Gourley C; Gabra H; Kessler M; Sehouli J; Darb-Esfahani S; Braicu EI
    Eur J Cancer; 2017 Jul; 79():214-225. PubMed ID: 28525846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Role of EGFR/p-EGFR in Patients With Nasopharyngeal Carcinoma: A Meta-Analysis.
    Chen X; Liang R; Lai L; Chen K; Zhu X
    Front Oncol; 2021; 11():697369. PubMed ID: 34490092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of performance status in metastatic renal cell carcinoma patients receiving tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Xu Y; Zhang Y; Wang X; Kang J; Liu X
    BMC Cancer; 2019 Feb; 19(1):168. PubMed ID: 30795756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between NM23 protein overexpression and prognostic value and clinicopathologic features of ovarian cancer: a meta-analysis.
    Fang J; Guo X; Zheng B; Han W; Chen X; Zhu J; Xie B; Liu J; Luan X; Yan Y; He Z; Li H; Qiao C; Yu J
    Arch Gynecol Obstet; 2018 Feb; 297(2):449-458. PubMed ID: 29274004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic roles of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in ovarian cancer: a meta-analysis of retrospective studies.
    Zhao Z; Zhao X; Lu J; Xue J; Liu P; Mao H
    Arch Gynecol Obstet; 2018 Apr; 297(4):849-857. PubMed ID: 29368160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis.
    Ruscito I; Darb-Esfahani S; Kulbe H; Bellati F; Zizzari IG; Rahimi Koshkaki H; Napoletano C; Caserta D; Rughetti A; Kessler M; Sehouli J; Nuti M; Braicu EI
    Gynecol Oncol; 2018 Jul; 150(1):151-157. PubMed ID: 29753392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen X; Meng F; Jiang R
    Front Oncol; 2021; 11():746976. PubMed ID: 34900692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.